We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-2.51%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$311M
AUM Growth
-$60.4M
Cap. Flow
-$15.3M
Cap. Flow %
-4.93%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$15.5M

Top Sells

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$22.2M
2
NRIX icon
Nurix Therapeutics
NRIX
+$8.58M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$116M 37.17%
9,671,643
– –
LYEL icon
2
Lyell Immunopharma
LYEL
$317M
$73.3M 23.57%
500,000
-164,109
-25% -$22.2M
ACRS icon
3
Aclaris Therapeutics
ACRS
$726M
$44.2M 14.21%
2,808,034
– –
KURA icon
4
Kura Oncology
KURA
$800M
$25.3M 8.13%
1,849,947
– –
PHVS icon
5
Pharvaris
PHVS
$2.28B
$24.9M 8.01%
3,246,926
– –
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.69B
$16.6M 5.33%
+690,000
New +$15.5M
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$6.25M 2.01%
1,787,094
– –
QSI icon
8
Quantum-Si Incorporated
QSI
$155M
$4.87M 1.57%
1,771,249
– –
NRIX icon
9
Nurix Therapeutics
NRIX
$2.41B
– –
-677,143
Closed -$8.58M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q3 2022 Portfolio in Review

As of Q3 2022, Foresite Capital Management IV held 9 positions worth $311M, down 16% from $371M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV withdrew a net $15.3M in Q3 2022, closing 1 position and reducing 1 holding. Its most notable exit was Nurix Therapeutics, an estimated $8.58M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management IV opened a new position in Syndax Pharmaceuticals worth $16.6M.

  • Foresite Capital Management IV's largest Q3 2022 buy was Syndax Pharmaceuticals: 690,000 shares worth $16.6M.
  • Foresite Capital Management IV's biggest Q3 2022 reduction was Lyell Immunopharma, cutting an estimated $22.2M.
  • Foresite Capital Management IV fully exited Nurix Therapeutics in Q3 2022, selling an estimated $8.58M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $311M portfolio in Q3 2022.
  • Foresite Capital Management IV opened 1 new position and closed 1 in Q3 2022.
  • Foresite Capital Management IV's portfolio value fell 16% quarter-over-quarter to $311M.

Based on Foresite Capital Management IV's 13F filing for Q3 2022, filed 14 Nov 2022.